Zacks Research Has Pessimistic Outlook of Bruker Q1 Earnings

Bruker Co. (NASDAQ:BRKR) – Analysts at Zacks Research cut their Q1 2026 earnings per share (EPS) estimates for Bruker in a research note issued on Monday, February 10th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $0.83 per share for the quarter, down from their prior forecast of $0.86. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.52% and a net margin of 9.41%.

A number of other analysts have also recently commented on the stock. Bank of America upped their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Wells Fargo & Company lowered their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. UBS Group started coverage on Bruker in a report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price objective on the stock. Guggenheim reissued a “buy” rating on shares of Bruker in a research note on Friday, January 17th. Finally, The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target on the stock in a research note on Thursday, December 5th. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $74.09.

Bruker Stock Up 2.0 %

Shares of NASDAQ:BRKR opened at $51.65 on Thursday. The company has a 50 day moving average price of $57.88 and a two-hundred day moving average price of $60.77. The company has a market capitalization of $7.83 billion, a PE ratio of 24.83, a PEG ratio of 3.81 and a beta of 1.16. Bruker has a 52 week low of $48.07 and a 52 week high of $94.86. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66.

Hedge Funds Weigh In On Bruker

Large investors have recently modified their holdings of the business. FMR LLC raised its holdings in Bruker by 21.4% during the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after acquiring an additional 2,521,904 shares in the last quarter. State Street Corp raised its stake in shares of Bruker by 9.6% during the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock worth $250,501,000 after purchasing an additional 318,808 shares in the last quarter. RTW Investments LP raised its stake in shares of Bruker by 1.1% during the 3rd quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock worth $240,406,000 after purchasing an additional 37,024 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Bruker by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company’s stock valued at $118,081,000 after buying an additional 20,273 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. grew its stake in shares of Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after buying an additional 666,617 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the stock in a transaction on Monday, November 18th. The shares were purchased at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the purchase, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This represents a 0.26 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.30% of the stock is currently owned by corporate insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.